Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

1.400 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avrobio Inc

< Previous 1 2 3 4 5 6 7 Next >
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML
Palantir stock is on the rise Thursday as PLTR investors react to a new $19 million contract for the big data and AI company. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday. 
Via InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning! 
Via InvestorPlace
AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024
AVRO stock results show that Avrobio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Avrobio Shares Are Rising Wednesday
AVROBIO Inc (NASDAQ: AVRO) shares are trading higher Wednesday after the company said it will explore strategic alternatives. 
Via Benzinga
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
  
Via Benzinga
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ZeroFox Holdings, Inc. (Nasdaq – ZFOX), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
AVROBIO and Tectonic Therapeutic Announce Merger
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AVROBIO to Explore Strategic Alternatives
From AVROBIO, Inc.
Via Business Wire
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program... 
Via Benzinga
Dow Tumbles 100 Points; Micron Technology Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping over 100 points on Monday. The Dow traded down 0.36% to 33,306.30 while the NASDAQ rose 0.39% to 12,707.21. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises Over 50 Points; Greenhill Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded down 0.20% to 33,359.71 while the NASDAQ rose 0.47% to 12,717.37. The S&P... 
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS). 
Via InvestorPlace
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
From AVROBIO, Inc.
Via Business Wire
Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpoints
Avrobio Inc (NASDAQ: AVRO) shares are trading higher after the company announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.